Stocks · News reference
Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the FDA for remibetadex to treat Niemann-Pick Disease Type C.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-29 AccNo: 0001213900-26-113564 Size: 306 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.